abstract |
The invention relates to a millimeter-scale drug delivery device (DDD) comprising a biodegradable polymeric matrix and an RNAi (RNA interference) agent that targets a prostate carcinoma-related gene, within said biodegradable polymeric matrix, for treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents. |